In the secondary analysis, the much less conservative but clinically meaningful criterion of stable response (outlined for a 50% or more reduction in MADRS from baseline for 2 weeks) was used. From the patients who reached stable response, twenty five.eight% during the esketamine group and fifty seven.6% during the placebo group relapsed, with a me